Double-Blind, Randomized, Placebo-Controlled Phase II Dose-Finding Study To Evaluate High-Dose Rifampin for Tuberculous Meningitis

Por Dian, S., Yunivita, V., Ganiem, A. R., Pramaesya, T., Chaidir, L., Wahyudi, K., Achmad, T. H., Colbers, A., te Brake, L., van Crevel, R., Ruslami, R., Aarnoutse, R.
Publicado no Antimicrob Agents Chemother (2018)

Exposure to Total and Protein-Unbound Rifampin Is Not Affected by Malnutrition in Indonesian Tuberculosis Patients

Por te Brake, L. H. M., Ruslami, R., Later-Nijland, H., Mooren, F., Teulen, M., Apriani, L., Koenderink, J. B., Russel, F. G., Burger, D. M., Alisjahbana, B., Wieringa, F., van Crevel, R., Aarnoutse, R. E.
Publicado no Antimicrob Agents Chemother (2015)

Pharmacokinetics of rifampicin in adult TB patients and healthy volunteers: a systematic review and meta-analysis

Por Stott, K E, Pertinez, H, Sturkenboom, M G G, Boeree, M J, Aarnoutse, R, Ramachandran, G, Requena-Méndez, A, Peloquin, C, Koegelenberg, C F N, Alffenaar, J W C, Ruslami, R, Tostmann, A, Swaminathan, S, McIlleron, H, Davies, G
Publicado no J Antimicrob Chemother (2018)